Export

ATC codes: L01DB02
Indication
Myeloid leukaemia ICD11 code: 2C03.1
INN
Daunorubicin
Medicine type
Chemical agent
List type
Complementary
Formulations
Parenteral > General injections > IV: 50 mg in vial (hydrochloride) powder for injection
EML status history
First added in 1999 (TRS 895)
Changed in 2002 (TRS 914)
Changed in 2007 (TRS 950)
Changed in 2015 (TRS 994)
Sex
All
Age
Adolescents and adults
Therapeutic equivalence
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Tags
Wikipedia
Summary of evidence and Expert Committee recommendations
In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for daunorubicin on the complementary list of the EML for use in treatment protocols for acute myelogenous leukaemia (AML) was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for AML is attached.